Durable Clinical Benefit Following Paclitaxel-Eluting Stent on the Outcome of Patients with Very Long Coronary Lesions Multicenter Registry 2-Year Results

> New Tokyo Circulation Research Group New Tokyo Hospital

Sunao Nakamura M.D, Ph.D. FACC, FESC, FSCAI

Background

PCI for very long lesions represents.....

1. High incidence of complication

Long Lesion


2. High incidence of restenosis

And more.....

- 1. Stent fracture
- 2. Stent thrombosis


Case LAD diffuse lesion

Pre



Post long TAXUS stenting


Long Lesion



Case LAD diffuse lesion

Follow up

Long Lesion



Aim

To evaluate the safety, efficacy and durability of Paclitaxel-eluting stent (TAXUS) implantation for very long coronary lesions (\geq 40mm).

To compare with a control group composed of patients with long coronary lesions treated with long bare metal stents in the same period.

Long Lesion

Inclusion Criteria

- Patients symptomatic for chest pain or demonstrating inducible ischemia with angiographic evidence of ≥75% diameter stenosis of Very long coronary artery stenosis. (RD; 2.5-4.0 mm in diameter,≥40 mm lesion length)
- All consecutive patients who underwent successful PCI using Paclitaxel-eluting stent (PES) and Bare Metal Stent(BMS).

Exclusion Criteria

- Contraindication to antiplatelet agents
- In-stent restenosis
- Chronic total occlusions
- Acute myocardial infarction within 48 hrs
- Grafted lesion



Procedure Technique


 Procedure strategy was mandated by the operator
The use of adjunctive devices and peri-procedual pharmacotherapy
Type of stents(BMS), Type of stenting, Thrombectomy Glycoprotein IIb/IIIa inhibitor, IVUS

 Usage of IVUS was indispensable in case of calcified lesion, undilatable lesion, rotational atherectomy case.

Vessel preparation was preceded by stenting.

Case LAD diffuse lesion

Long Lesion



Case LAD diffuse lesion

Just Stenting

Diffuse ISR


Long Lesion

Follow-up

Pre



Case LAD diffuse calcified lesion



Long Lesion

Long Lesion

Antiplatelet Therapy

After SES implantation.....12 months long
with Aspirin 100 mg /day
Clopidogrel 75 mg /day

After BMS implantation.....1 month long
with Aspirin 100 mg /day
Ticlopidine 200 mg /day



Study End Points Primary End Points ✤ 30 days MACE ✤ 12, 24 months MACE **Secondary End Points** 12, 24 months angiographic restenosis rate ✤ 12, 24 months TLR

Definitions

Angiographic success: Recanalization of the artery with <50% residual diameter stenosis with restoration of TIMI 3 flow.

Long Lesion

Clinical success: Angiographic success without in-hospital MACE

MACE: Death, QMI, CABG and Re-PCI

Target Lesion Revascuraization (TLR): Any surgical or re-PCI motivated by a significant narrowing within the stent or in the 5-mm distal or proximal peristent segment

Angiographic Analysis

All data were entered into the Asian multi-center DES-Very Long Lesion registry database at the New Tokyo Hospital. Quantitative coronary angiographic analysis was performed by a CMS quantitative analysis system (QCA-CMS, version 3.0, MEDIS, The Netherlands). Minimal lumen diameter, reference diameter, and percent diameter stenosis were measured before and after the procedure and at follow-up; the results from the single "worst" view were recorded.

Long Lesion


Statistical Analysis

All data were entered into the Asian multi-center DES-Very long lesion registry database at the New Tokyo Hospital. Data are expressed as mean ± SD unless otherwise indicated. For comparison of paired data, dependent t test analyses were used. For non-paired data, analyses were used to test differences in categorical variables.

Long Lesion

-Multicenter Registry in Asia-

New Tokyo Hospital **Sunao Nakamura M.D.**, Ph.D. (Japan) Damansara Heart Center **Selvan** Muthusamy M.D. (Malaysia) Konyang University Hospital **Jang-Ho Bae M.D.** (Korea) Husada Hospital Yeo Hans Cahyadi M.D. (Indonesia) Chest Disease Institute **E** Sudaratana Tansuphaswadikul M.D. (Thailand) Siriaj Hospital **E** Damras Tresukosol M.D. (Thailand) King Chulalongkorn Wasan Udayachalerm M.D. (Thailand) Memorial Hospital



Interventional Procedure Stenting Procedure

Following the adequate vessel preparation, coronary stents were implanted, adjunct high-pressure balloon inflation (14 to 20 atm) was added in all cases.

Long Lesion

Bare Metal Stent Paclitaxel-Eluting Stent Express stent 6% Terumo stent 21% Medtronic TAXUS 42% 100% **Multi-Link** 31% **TCT Asia Pacific 2008**

Baseline Characteristics

Long Lesion

	BMS	TAXUS	р
Patients (n)	306	288	_
Age (yrs)	67.8±10.5	70.8±10.5	NS
Male (%)	69.9	72.9	NS
Risk factors (%)			
Hypertension	51.0	62.5	NS
Hyperlipidemia	32.0	30.5	NS
Diabetes	33.0	34.3	NS
Smoking	52.3	59.0	< NS
Previous MI (%)	13.4	10.4	NS
LVEF (%)	47.6	45.8	NS
Multi vessel disease(%)	70.6	78.1	NS

Data are presented as the wear value \pm SD are number (%) of patients. LVEF: left ventricular ejection fraction MI: myocardial infarction

Lesion Characteristics

Long Lesion

	BMS	TAXUS	р
Patients / lesions (n)	306 / 379	288 / 322	-
Number of CAD (%) One	28.8	22.9	<u>_</u> ۲_
Two	31.0	33.1	NS
	40.2	44.0	
Target vessel (%) LAD	51.2	52.8	ר (כ
LCX	27.0	31.1	NS
RCA	21.8	16.1	
AHA / ACC lesion type (%)		10.0	
B1 Do	20.6	19.3	
B2 C	35.1 44.3	38.9	NS
Calcified lesion	42.0	60.2	_<0.05

Data are presented as the number (%) of lesion.



Clinical Results (In-Hospital)

	BMS (n=306)	TAXUS (n=288)	р		
Angiographic success (%)	98.0	97.2	NS		
Clinical success (%)	98.0	97.9	NS		
MACE at 30 days (%)	1.3	1.4	NS		
ACO / SAT (%)	0.3	0.3	NS		
Q-MI (%)	1.3	1.4			
Untreated dissection (%)	5.2	7.6	NS		
No-flow (%)	1.3	1.0	NS		
Slow-flow (%)	2.9	3.8	NS		
Side branch occlusion (%)	3.9	4.9	NS		
MACE: major adverse cardiac event (death. MI. CABG)					

MACE: major adverse cardiac event (death, MI, CABG) ACO: acute occlusion SAT: sub acute thrombotic occlusion

Long Lesion

Long Lesion

Procedure Characteristics

	BMS	TAXUS	р
Patients / lesions	306 / 379	288 / 322	- //
Balloon / artery ratio	1.06 ± 0.14	0.92±0.14	NS
Maximum pressure (balloon)	12.4±6.5	12.5±7.8	NS
Stent / artery ratio (mean)	1.08±0.20	1.04 ± 0.30	NS
Maximum pressure (stent)	16.8±7.0	20.8±10.2	<0.05
Stent / lesion length ratio	0.68+0.24	1.23±0.28	<0.05
Rotablator use (%)	25.5	10.1	<0.05
IVUS use (%)	47.0	11.1	<0.05
Number of the stents / lesion	1.4	2.6	<0.05
(n:mean)			
TCT Asia Pacific 2008		7	

Quantitative Coronary Angiographic Analysis = Baseline =

	BMS	TAXUS	р
Patients / lesions (n)	306 / 374	288 / 322	s <u> </u>
Ref. diameter (mm:proximal)	2.80±0.64	2.86 ± 0.68	NS
Minimum lumen diameter (m	im)		
Pre procedure	$0.58 {\pm} 0.44$	0.59±0.71	NS
Post procedure	2.36 ± 0.65	2.29 ± 0.63	NS
Lesion length (mm)	45.8±11.3	45.9±10.6	NS
Acute gain (mm)	1.90±0.60	$1.70 {\pm} 0.79$	NS
Stent length / Lesion length ratio	0.68±0.24	1.23±0.28	0.03

Long Lesion

Quantitative Coronary Angiographic Analysis = Follow-Up =

	BMS	TA> One year	(US Two year	p
Angiographic follow-up rate (%)	94.8	79.9	69.1	
Reference diameter (mm)	2.82 ± 0.66	2.83±0.69	2.82±0.70	NS
Minimum lumen diameter (mm)	1.55 ± 0.66	1.95±0.60	1.90±0.70	0.03
Restenosis (%) (12 mo)	43.5	18.8	19.4	0.01
TLR (%) (12 mo)	32.0	14.9	15.6	0.01


TLR: target lesion revascularization.

Two Year Clinical Follow-Up


BMS	TA	XUS	р
	One year	Two year	
306	288	288	
0	0	0	-
4	4	4	NS
(1 3 %)	(1.4%)	(1.4%)	
120	43*	45*	0.01
(39.2%)	(14.9%)	(15.6%)	
4	0	0	NS
(1.3%)	(0%)	(0%)	
124	47*	49*	0.01
(40.5%)	(16.3%)	(17.0%)	
128	47*	49*	0.01
(41.8%)	(16.3%)	(17.0%)	
	$\begin{array}{c} 306\\ 0\\ \\ 4\\ (1,3\%)\\ \\ 120\\ (39.2\%)\\ \\ \\ 4\\ (1.3\%)\\ \\ 124\\ (40.5\%)\\ \\ 128 \end{array}$	$\begin{array}{c c} & One \ year \\ \hline 306 & 288 \\ 0 & 0 \\ \hline 4 & 4 \\ (1.3\%) & (1.4\%) \\ \hline 120 & 43^* \\ (39.2\%) & (14.9\%) \\ \hline 4 & 0 \\ (1.3\%) & (0\%) \\ \hline 124 & 47^* \\ (40.5\%) & (16.3\%) \\ \hline 128 & 47^* \\ \end{array}$	$\begin{array}{c cccc} \hline & & & & & & & & \\ \hline & & & & & & & \\ \hline & & & &$


Long Lesion

In-hospital Clinical Outcome 30 Days MACE



Long Lesion





CYPHER[™] Cordis, Johnson & Johnson Sirolimus-Eluting Stent



TAXUS™ Boston Scientific Paclitaxel-Eluting Stent




ENDEAVOR™ Medtronic Zotarolimus-Eluting Stent



JANUS™ sorin Biomedica Tacrolimus-Eluting Carbostent





Genous[™] OrbusNeich EPC-Capture Stent




Study Patients

Patient cohort includes 922 patients with Very long lesion in our data-base, treated with Sirolimus-eluting stent (SES), Paclitaxeleluting stent (PES), Zotarolimus-eluting stent (Endeavor: ZES), Tacrolimus-eluting stent (JANUS: TES) and EPC capture stent (ECS)





Stent Thrombosis: 1yr




Multivariate Predictors of Thrombosis

	OR	95% CI	P	
LVEF	0.89	0.80 – 0.98	0.02	
Stent lengh	1.08	0.80 – 1.46	0.60	
lesion length	1.00	0.67 – 1.50	0.99	
Bifurcation stenting	1.40	0.16 – 12.23	0.76	




Stent Thrombosis..... When ? ARC Definite / Probable




Stent Thrombosis in J-Cypher Registry

ARC Definite / Probable



Stent Thrombosis in J-Cypher and Bern/Rotterdam study



Wenaweser P., ESC 2006, Oral Presentation # 1012

Conclusions

1. Long TAXUS stent implantation for very long lesions was safe and feasible.

 Compared with BMS, long TAXUS stenting were associated with reduction of restenosis rate and target lesion revascularization and these clinical benefit is durable at least 2 years.